Analysis

UK Justices' Regeneron Ruling Puts Hurdle In Biotech IP Race

Law360, London (June 24, 2020, 9:47 PM BST) -- The U.K. Supreme Court made clear Wednesday that a company with a revolutionary patent still can't monopolize a broad range of products without the patent explaining how they'd all be made, a decision experts say will exacerbate the pressure to stake a biotech field claim as quickly as possible.

In its 4-1 ruling, Britain's top court emphasized that patents must include enough detail for someone else to reproduce the full range of inventions that the patent would cover.

The two patents at issue provided Regeneron Pharmaceuticals Inc. with a monopoly over the creation of a range of transgenic mice used for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!